Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors
{{output}}
Antibody-drug conjugates (ADC), a combination of cytotoxic drugs and antibodies, have emerged as a rising star in cancer therapy. Disitamab vedotin (RC48), a novel ADC targeting human epidermal growth factor receptor 2 (HER2), is currently being explored in a ... ...
